Evidence-Based Management of Systemic Sclerosis

Introduction to Systemic Sclerosis Management

The optimal treatment approach for systemic sclerosis requires organ-specific therapies tailored to the patient's disease manifestations, with mycophenolate mofetil as first-line therapy for interstitial lung disease and combination therapy for pulmonary arterial hypertension 1

Immunosuppressive agents are the cornerstone of treatment for early diffuse cutaneous SSc, with mycophenolate mofetil having surpassed cyclophosphamide as the preferred initial therapy 2, 1
For patients with rapidly progressive early dcSSc at high risk of mortality, autologous hematopoietic stem cell transplantation should be considered as it can improve survival 1
Other effective options for skin manifestations include methotrexate, rituximab, and tocilizumab 3

Mycophenolate mofetil is the first-line treatment for SSc-ILD 4, 1
For progressive pulmonary fibrosis, add nintedanib as anti-fibrotic therapy 2, 1
Alternative immunosuppressive options include cyclophosphamide, rituximab, or tocilizumab 4
Lung transplantation should be considered for end-stage lung fibrosis, with outcomes comparable to other chronic diseases 4
Ensure all vaccines are up to date, especially pneumococcal vaccines, influenza, and COVID-19 4
Oxygen therapy is indicated if hypoxia is present, which can reduce dyspnea and mitigate pulmonary hypertension development 4

Initial combination therapy is recommended for SSc-PAH, typically with phosphodiesterase-5 inhibitors and endothelin receptor antagonists 2, 1
For pulmonary hypertension secondary to ILD, consider inhaled treprostinil which has been shown to improve exercise capacity and reduce NT-proBNP levels 4

First-line treatment for Raynaud's phenomenon is dihydropyridine calcium channel blockers 2, 1
For prevention of digital ulcers, use calcium channel blockers first, followed by PDE-5 inhibitors, then ERAs 1
Fluoxetine may be considered for SSc-related Raynaud's phenomenon 5, 6

Combination therapies addressing multiple pathogenic mechanisms are likely needed to impact long-term survival 3
Regular screening for organ complications is essential, as early intervention may prevent irreversible damage 1
Despite treatment advances, many SSc manifestations still lack evidence-based therapies, highlighting the need for continued research 6